Tuberculosis - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H1 2018’, provides an overview of the Tuberculosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tuberculosis

- The report reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Tuberculosis therapeutics and enlists all their major and minor projects

- The report assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Tuberculosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Tuberculosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abera Bioscience AB

AGILeBiotics BV

Akshaya Bio Inc

Archivel Farma SL

AstraZeneca Plc

Aucta Pharmaceuticals LLC

BioLingus AG

Bioversys AG

Celgene Corp

Chongqing Zhifei Biological ...

Abera Bioscience AB

AGILeBiotics BV

Akshaya Bio Inc

Archivel Farma SL

AstraZeneca Plc

Aucta Pharmaceuticals LLC

BioLingus AG

Bioversys AG

Celgene Corp

Chongqing Zhifei Biological Products Co Ltd

Consegna Pharma Inc

Crestone Inc

Daiichi Sankyo Co Ltd

Demuris Ltd

Eisai Co Ltd

Eli Lilly and Co

EpiVax Inc

Evotec AG

FIT Biotech Oy

GangaGen Inc

GC Pharma

GlaxoSmithKline Plc

Globeimmune Inc

Hager Biosciences LLC

Hsiri Therapeutics LLC

Immodulon Therapeutics Ltd

Immunitor Inc

ImmunoBiology Ltd

Innovare R & D SA De CV

Inovio Pharmaceuticals Inc

Johnson & Johnson

LegoChem Biosciences Inc

Matinas BioPharma Holdings Inc

Merck & Co Inc

Microbiotix Inc

Novartis AG

NovoBiotic Pharmaceuticals LLC

Otsuka Holdings Co Ltd

Pfizer Inc

QureTech Bio AB

Qurient Co Ltd

Recce Ltd

Rodos BioTarget GmbH

Sanofi

Sanofi Pasteur SA

Sequella Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

Theravectys SA

TVAX Biomedical Inc

Vaccibody AS

Vakzine Projekt Management GmbH

Vaxil Bio Therapeutics Ltd

Vaxine Pty Ltd

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Tuberculosis - Overview 7

Tuberculosis - Therapeutics Development 8

Tuberculosis - Therapeutics Assessment 31

Tuberculosis - ...

Table of Contents

Table of Contents 2

Introduction 6

Tuberculosis - Overview 7

Tuberculosis - Therapeutics Development 8

Tuberculosis - Therapeutics Assessment 31

Tuberculosis - Companies Involved in Therapeutics Development 41

Tuberculosis - Drug Profiles 65

Tuberculosis - Dormant Projects 299

Tuberculosis - Discontinued Products 309

Tuberculosis - Product Development Milestones 310

Appendix 319

List of Tables

List of Tables

Number of Products under Development for Tuberculosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Tuberculosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Tuberculosis - Pipeline by Abera Bioscience AB, H1 2018

Tuberculosis - Pipeline by AGILeBiotics BV, H1 2018

Tuberculosis - Pipeline by Akshaya Bio Inc, H1 2018

Tuberculosis - Pipeline by Archivel Farma SL, H1 2018

Tuberculosis - Pipeline by AstraZeneca Plc, H1 2018

Tuberculosis - Pipeline by Aucta Pharmaceuticals LLC, H1 2018

Tuberculosis - Pipeline by BioLingus AG, H1 2018

Tuberculosis - Pipeline by Bioversys AG, H1 2018

Tuberculosis - Pipeline by Celgene Corp, H1 2018

Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018

Tuberculosis - Pipeline by Consegna Pharma Inc, H1 2018

Tuberculosis - Pipeline by Crestone Inc, H1 2018

Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Tuberculosis - Pipeline by Demuris Ltd, H1 2018

Tuberculosis - Pipeline by Eisai Co Ltd, H1 2018

Tuberculosis - Pipeline by Eli Lilly and Co, H1 2018

Tuberculosis - Pipeline by EpiVax Inc, H1 2018

Tuberculosis - Pipeline by Evotec AG, H1 2018

Tuberculosis - Pipeline by FIT Biotech Oy, H1 2018

Tuberculosis - Pipeline by GangaGen Inc, H1 2018

Tuberculosis - Pipeline by GC Pharma, H1 2018

Tuberculosis - Pipeline by GlaxoSmithKline Plc, H1 2018

Tuberculosis - Pipeline by Globeimmune Inc, H1 2018

Tuberculosis - Pipeline by Hager Biosciences LLC, H1 2018

Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H1 2018

Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, H1 2018

Tuberculosis - Pipeline by Immunitor Inc, H1 2018

Tuberculosis - Pipeline by ImmunoBiology Ltd, H1 2018

Tuberculosis - Pipeline by Innovare R & D SA De CV, H1 2018

Tuberculosis - Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Tuberculosis - Pipeline by Johnson & Johnson, H1 2018

Tuberculosis - Pipeline by LegoChem Biosciences Inc, H1 2018

Tuberculosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2018

Tuberculosis - Pipeline by Merck & Co Inc, H1 2018

Tuberculosis - Pipeline by Microbiotix Inc, H1 2018

Tuberculosis - Pipeline by Novartis AG, H1 2018

Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2018

Tuberculosis - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Tuberculosis - Pipeline by Pfizer Inc, H1 2018

Tuberculosis - Pipeline by QureTech Bio AB, H1 2018

Tuberculosis - Pipeline by Qurient Co Ltd, H1 2018

Tuberculosis - Pipeline by Recce Ltd, H1 2018

Tuberculosis - Pipeline by Rodos BioTarget GmbH, H1 2018

Tuberculosis - Pipeline by Sanofi, H1 2018

Tuberculosis - Pipeline by Sanofi Pasteur SA, H1 2018

Tuberculosis - Pipeline by Sequella Inc, H1 2018

Tuberculosis - Pipeline by Shionogi & Co Ltd, H1 2018

Tuberculosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Tuberculosis - Pipeline by Target Medicals LLC, H1 2018

Tuberculosis - Pipeline by Theravectys SA, H1 2018

Tuberculosis - Pipeline by TVAX Biomedical Inc, H1 2018

Tuberculosis - Pipeline by Vaccibody AS, H1 2018

Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2018

Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2018

Tuberculosis - Pipeline by Vaxine Pty Ltd, H1 2018

Tuberculosis - Pipeline by Vichem Chemie Research Ltd, H1 2018

Tuberculosis - Dormant Projects, H1 2018

Tuberculosis - Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Tuberculosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Tuberculosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports